Key result
Dual antiplatelet therapy with aspirin and clopidogrel for 6 months did not significantly reduce target lesion revascularization at 12 months compared to aspirin alone (25% vs 32.4%, p=0.35).
Why the study?
Does 6 months of dual antiplatelet therapy (aspirin and clopidogrel) reduce target lesion revascularization at 12 months in patients with peripheral artery disease undergoing endovascular treatment compared to aspirin alone?
Population
80 patients with peripheral artery disease undergoing balloon angioplasty ± stenting in the femoropopliteal…
Comparison
Aspirin and clopidogrel pre- and… vs Aspirin and placebo pre- and post-intervention…
Design
RCT, randomly assigned, double-blinded and placebo-controlled
Follow-up
12 months
Authors
Loading...
No sustained TLR benefit with 6-month DAPT after endovascular PAD treatment; challenges routine use and supports trials of shorter or single-agent regimens.
RCT (n=80)
Double-blind
randomly assigned
No
Does 6 months of dual antiplatelet therapy (aspirin and clopidogrel) reduce target lesion revascularization at 12 months in patients with peripheral artery disease undergoing endovascular treatment compared to aspirin alone?
Absolute Event Rate: 25% vs 32.4%
p-value: p=0.35
The reduction in target lesion revascularization seen at 6 months with dual antiplatelet therapy in PAD patients does not persist at 12 months after clopidogrel is discontinued.
Strobl et al. (2013) conducted an RCT in Peripheral Artery Disease (n=80). Aspirin and clopidogrel vs. Aspirin and placebo was evaluated on Target lesion revascularization (TLR) at 12 months (p=0.35). Dual antiplatelet therapy with aspirin and clopidogrel for 6 months did not significantly reduce target lesion revascularization at 12 months compared to aspirin alone (25% vs 32.4%, p=0.35).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: